 This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily BID compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the trial. 